Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Absorbs 130 Medical Representatives From Merck KGaA

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo announced July 16 that its German subsidiary agreed to take in 130 medical representatives from Merck KGaA. Since Merck KGaA's decision not to continue marketing activities to medical facilities for drugs whose patents have expired, Daiichi Sankyo decided to take half of the medical representatives and merge them into its own sales force. Currently, 70 percent of Daiichi Sankyo's sales come from the Japanese domestic market. The company hopes to reach 70 percent of sales from the overseas market by 2015. The company is rapidly expanding business in Europe, and in Germany, it has acquired bio-pharmaceutical company Morphosys and antibody maker U3 Pharma. (Click here for more - Japanese language) "In Germany Daiichi Sankyo Takes In 130 Medical Representatives From Merck" - NNA News (7/18/08)

You may also be interested in...

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

Azurity’s Xatmep Promotional Email To Healthcare Professionals Gets Dinged By US FDA

In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts